ABX advanced biochemical compounds GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ABX advanced biochemical compounds GmbH
Novartis Delighted With Xiidra Deal Despite Eye-Watering Price
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying Endocyte for a whopping $2.1bn., highlighting the company's emphasis on building in radiopharmaceuticals.
Deals Shaping The Medical Industry, November 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
- Contract Research, Toxicology Testing-CRO
- Research, Analytical Equipment & Supplies
- Radiopharmaceuticals, Contrast Agents
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.